Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|March 14, 2024
Dr Singh on the Utility of Radiation Therapy in Lung Cancer
Author(s)Raj Singh, MD
Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.
Advertisement
Raj Singh, MD, assistant professor, Radiation Oncology, The Ohio State University, Comprehensive Cancer Center (OSUCC) OSUCC– James, discusses the utility of radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.
Advertisement
Related to this article
An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5